Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
RGNX
RGNX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RGNX News
REGENXBIO Faces Class Action Lawsuit
1d ago
Globenewswire
Biotech Sector Faces FDA Turmoil
4d ago
Fool
REGENXBIO Faces FDA Challenges for Gene Therapy Approval
5d ago
Newsfilter
REGENXBIO's RGX-121 BLA Accepted by FDA Under Accelerated Approval Pathway
5d ago
Benzinga
REGENXBIO's RGX-121 Application Rejected by FDA
5d ago
NASDAQ.COM
Regenxbio's Gene Therapy Faces FDA Rejection
5d ago
seekingalpha
Credo Technology Raises Revenue Guidance Significantly
5d ago
Benzinga
Regenxbio's RGX-121 Faces FDA Approval Setback
5d ago
stocktwits
REGENXBIO's Gene Therapy Denied by FDA
5d ago
stocktwits
Regenxbio Faces FDA Clinical Hold Investigation
Jan 30 2026
PRnewswire
Regenxbio Faces Investigation Over FDA Clinical Holds
Jan 29 2026
PRnewswire
Regenxbio Faces FDA Clinical Hold Investigation
Jan 29 2026
Newsfilter
REGENXBIO Faces FDA Clinical Hold on Gene Therapy RGX-111
Jan 28 2026
stocktwits
REGENXBIO Faces FDA Clinical Hold Investigation
Jan 28 2026
Globenewswire
REGENXBIO's Gene Therapy Programs Face FDA Clinical Hold
Jan 28 2026
Benzinga
REGENXBIO's Gene Therapies Face FDA Clinical Hold
Jan 28 2026
stocktwits
Show More News
